Severe radiation dermatitis in patients with locally advanced head and neck cancer treated with concurrent radiation and cetuximab
- PMID: 19487913
- DOI: 10.1097/COC.0b013e318193125c
Severe radiation dermatitis in patients with locally advanced head and neck cancer treated with concurrent radiation and cetuximab
Abstract
Objectives: A phase III trial has shown the superiority of concurrent cetuximab and radiotherapy versus radiotherapy alone for the treatment of locally advanced head and neck cancer (HNC). We evaluated our institution's experience of patients treated with concurrent cetuximab and radiotherapy to determine the rate of serious (≥ grade 3) radiation dermatitis. We also sought to more fully describe and characterize the grade 4 dermatitis that these patients develop.
Methods: We performed a retrospective review of HNC patients who were treated with concurrent cetuximab and radiation. We included patients treated in either the definitive or loco-regionally recurrent setting with nonmetastatic disease who received their first dose of cetuximab from March 1, 2006 to January 1, 2008. We found 115 patients who fit our search.
Results: Serious radiation dermatitis was noted in 26 (23%) patients, with 22 patients developing grade 3 dermatitis and 4 patients developing grade 4 dermatitis. All 4 patients who developed grade 4 dermatitis did so within the radiation field. The dermatitis was manifested by spontaneous bleeding from the involved skin, and in 1 case, skin necrosis. These toxicities developed during the fifth week of treatment.
Conclusions: Treatment with concurrent radiation and cetuximab for locally advanced HNC is a relatively new treatment modality, and the toxicities of this regimen are becoming better understood. We believe that the serious skin toxicities that these patients develop when treated with concomitant cetuximab occur more frequently than when patients are treated with concurrent cisplatin, although further study is needed to confirm this.
Similar articles
-
Grade 3/4 dermatitis in head and neck cancer patients treated with concurrent cetuximab and IMRT.Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):110-7. doi: 10.1016/j.ijrobp.2010.05.018. Epub 2010 Aug 21. Int J Radiat Oncol Biol Phys. 2011. PMID: 20732757
-
High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes.Radiother Oncol. 2009 Feb;90(2):166-71. doi: 10.1016/j.radonc.2008.09.007. Epub 2008 Oct 30. Radiother Oncol. 2009. PMID: 18977050
-
Development and management of severe cutaneous side effects in head-and-neck cancer patients during concurrent radiotherapy and cetuximab.Strahlenther Onkol. 2008 Feb;184(2):105-10. doi: 10.1007/s00066-008-1829-z. Strahlenther Onkol. 2008. PMID: 18259703
-
Management of dermatitis in patients with locally advanced squamous cell carcinoma of the head and neck receiving cetuximab and radiotherapy.Oral Oncol. 2012 Apr;48(4):293-7. doi: 10.1016/j.oraloncology.2011.10.019. Epub 2011 Dec 3. Oral Oncol. 2012. PMID: 22137799 Review.
-
Treatment of head and neck cancers: issues for clinical pharmacists.Pharmacotherapy. 2009 May;29(5):578-92. doi: 10.1592/phco.29.5.578. Pharmacotherapy. 2009. PMID: 19397465 Review.
Cited by
-
Retrospective evaluation of concomitant cetuximab and radiotherapy tolerance for locoregional advanced head and neck squamous cell carcinoma treatment in patients unfit for platinum-based chemotherapy.Eur Arch Otorhinolaryngol. 2017 Jul;274(7):2883-2889. doi: 10.1007/s00405-017-4550-7. Epub 2017 Apr 5. Eur Arch Otorhinolaryngol. 2017. PMID: 28382396
-
Radiotherapy and "new" drugs-new side effects?Radiat Oncol. 2011 Dec 21;6:177. doi: 10.1186/1748-717X-6-177. Radiat Oncol. 2011. PMID: 22188921 Free PMC article. Review.
-
Acute toxicity in 14 patients with locally advanced head and neck squamous cell carcinoma treated with concurrent cetuximab and radiotherapy.Radiol Med. 2012 Feb;117(1):125-32. doi: 10.1007/s11547-011-0716-3. Epub 2011 Sep 2. Radiol Med. 2012. PMID: 21892718 English, Italian.
-
Strategy of Using Intratreatment Hypoxia Imaging to Selectively and Safely Guide Radiation Dose De-escalation Concurrent With Chemotherapy for Locoregionally Advanced Human Papillomavirus-Related Oropharyngeal Carcinoma.Int J Radiat Oncol Biol Phys. 2016 Sep 1;96(1):9-17. doi: 10.1016/j.ijrobp.2016.04.027. Epub 2016 May 7. Int J Radiat Oncol Biol Phys. 2016. PMID: 27511842 Free PMC article. Clinical Trial.
-
Survival, recurrence and toxicity of HNSCC in comparison of a radiotherapy combination with cisplatin versus cetuximab: a meta-analysis.BMC Cancer. 2016 Aug 26;16(1):689. doi: 10.1186/s12885-016-2706-2. BMC Cancer. 2016. PMID: 27565887 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical